OBJECTIVES: The orexigenic hormone ghrelin circulates mainly in two forms, acylated and desacyl ghrelin. We evaluated the impact of obesity and obesity-associated type 2 diabetes (T2D) on ghrelin forms and the potential role of acylated and desacyl ghrelin in the control of adipogenesis in humans. METHODS: Plasma concentrations of the different ghrelin forms were measured in 80 subjects. The expression of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R) was analyzed in omental adipose tissue using western blot and immunohistochemistry, and the effect of acylated ghrelin and desacyl ghrelin (0.1-1000 pmol l(-1)) on adipogenesis was determined in vitro in omental adipocytes. RESULTS: Circulating concentrations of acylated ghrelin were increased, whereas desacyl ghrelin levels were decreased, in obesity and obesity-associated T2D. Body mass index, waist circumference, insulin and HOMA (homeostasis model assessment) index were positively correlated with acylated ghrelin levels. Obese individuals showed a lower protein expression of GHS-R in omental adipose tissue. In differentiating omental adipocytes, incubation with both acylated and desacyl ghrelin significantly increased PPARgamma (peroxisome proliferator-activated receptor gamma) and SREBP1 (sterol-regulatory element binding protein-1) mRNA levels, as well as several fat storage-related proteins, including acetyl-CoA carboxylase, fatty acid synthase, lipoprotein lipase and perilipin. Consequently, both the ghrelin forms stimulated intracytoplasmatic lipid accumulation. CONCLUSIONS: Both acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Given the lipogenic effect of acylated ghrelin on visceral adipocytes, the herein-reported elevation of its circulating concentrations in obese individuals may play a role in excessive fat accumulation in obesity.
OBJECTIVES: The orexigenic hormone ghrelin circulates mainly in two forms, acylated and desacyl ghrelin. We evaluated the impact of obesity and obesity-associated type 2 diabetes (T2D) on ghrelin forms and the potential role of acylated and desacyl ghrelin in the control of adipogenesis in humans. METHODS: Plasma concentrations of the different ghrelin forms were measured in 80 subjects. The expression of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R) was analyzed in omental adipose tissue using western blot and immunohistochemistry, and the effect of acylated ghrelin and desacyl ghrelin (0.1-1000 pmol l(-1)) on adipogenesis was determined in vitro in omental adipocytes. RESULTS: Circulating concentrations of acylated ghrelin were increased, whereas desacyl ghrelin levels were decreased, in obesity and obesity-associated T2D. Body mass index, waist circumference, insulin and HOMA (homeostasis model assessment) index were positively correlated with acylated ghrelin levels. Obese individuals showed a lower protein expression of GHS-R in omental adipose tissue. In differentiating omental adipocytes, incubation with both acylated and desacyl ghrelin significantly increased PPARgamma (peroxisome proliferator-activated receptor gamma) and SREBP1 (sterol-regulatory element binding protein-1) mRNA levels, as well as several fat storage-related proteins, including acetyl-CoA carboxylase, fatty acid synthase, lipoprotein lipase and perilipin. Consequently, both the ghrelin forms stimulated intracytoplasmatic lipid accumulation. CONCLUSIONS: Both acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Given the lipogenic effect of acylated ghrelin on visceral adipocytes, the herein-reported elevation of its circulating concentrations in obese individuals may play a role in excessive fat accumulation in obesity.
Authors: Arlet V Nedeltcheva; Jennifer M Kilkus; Jacqueline Imperial; Dale A Schoeller; Plamen D Penev Journal: Ann Intern Med Date: 2010-10-05 Impact factor: 25.391
Authors: A Rodríguez; J Gómez-Ambrosi; V Catalán; S Ezquerro; L Méndez-Giménez; S Becerril; P Ibáñez; N Vila; M A Margall; R Moncada; V Valentí; C Silva; J Salvador; G Frühbeck Journal: Int J Obes (Lond) Date: 2016-04-25 Impact factor: 5.095
Authors: Victoria Catalán; Javier Gómez-Ambrosi; Amaia Rodríguez; Beatriz Ramírez; Fernando Rotellar; Victor Valentí; Camilo Silva; María J Gil; José Manuel Fernández-Real; Javier Salvador; Gema Frühbeck Journal: Mol Med Date: 2011-07-05 Impact factor: 6.354
Authors: William Gibson; Jianhua Liu; Bruce Gaylinn; Michael O Thorner; Graydon S Meneilly; Sandra L Babich; David Thompson; Jean-Pierre Chanoine Journal: Metabolism Date: 2009-12-16 Impact factor: 8.694
Authors: S Heinonen; L Saarinen; J Naukkarinen; A Rodríguez; G Frühbeck; A Hakkarainen; J Lundbom; N Lundbom; K Vuolteenaho; E Moilanen; P Arner; S Hautaniemi; A Suomalainen; J Kaprio; A Rissanen; K H Pietiläinen Journal: Int J Obes (Lond) Date: 2014-02-19 Impact factor: 5.095